Wenzhi Tian, MD
Dr. Wenzhi Tian founded ImmuneOnco in 2015 with focus on developing tumor immunotherapeutics, including checkpoint modulators and target-activated NK (TANK) cell products, for unmet medical needs in China and worldwide.
Dr. Tian returned to China in 2011 from ImClone Systems and established Huabo Biopharm Co., Ltd where he worked as CEO until 2015. Dr. Tian was Principal Research Scientist at ImClone Systems between 2006 and 2011. Prior to joining ImClone Systems, He was CSO of Aoko Biotechnology Ltd. from July 2005 to December 2005, where he led vaccine development efforts against HIV using yeast technology platform.
Prior to joining Aoko Biotechnology, he was a Senior Research Associate from 2001 to 2005 at the Department of Medicine, Weill Medical College of Cornell University, with primary focus on cloning and characterizing novel genes from B lymphocytes. From 1997 to 2001, he was a postdoctoral fellow at the Department of Rheumatology and Allergy & Immunology, North Shore University Hospital, NYU School of Medicine, dedicated to cloning and characterizing genes involved in immunoglobulin class switch recombination.
Dr. Tian received his M.D. degree from Henan Medical University in 1987 and his Ph.D. degree in 1997 at the Department of Neurology and Clinical Immunology, Karolinska Institute, Huddinge Unversity Hospital, Huddinge, Sweden.
- Next：Xiaoyong Yu, MBA